In the past week, VRDN stock has gone down by -15.99%, with a monthly decline of -11.15% and a quarterly plunge of -28.65%. The volatility ratio for the week is 6.62%, and the volatility levels for the last 30 days are 6.61% for Viridian Therapeutics Inc The simple moving average for the past 20 days is -12.82% for VRDN’s stock, with a -3.11% simple moving average for the past 200 days.
Is It Worth Investing in Viridian Therapeutics Inc (NASDAQ: VRDN) Right Now?
VRDN has 36-month beta value of 1.36. Analysts have mixed views on the stock, with 10 analysts rating it as a “buy,” 5 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for VRDN is 70.47M, and currently, short sellers hold a 17.10% ratio of that float. The average trading volume of VRDN on January 15, 2025 was 1.33M shares.
VRDN) stock’s latest price update
The stock price of Viridian Therapeutics Inc (NASDAQ: VRDN) has plunged by -5.12 when compared to previous closing price of 17.77, but the company has seen a -15.99% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2024-12-19 that Company reported positive phase 3 THRIVE-2 study results using veligrotug in treating chronic thyroid eye disease patients, positioning it to file a BLA in the 2nd half 2025. The company is developing VRDN-003, an improved subcutaneous version of veligrotug for TED patients, with phase 3 REVEAL-1 and REVEAL-2 topline data expected in early 2026. Promising pipeline candidates include FcRn inhibitors VRDN-006 and bispecific VRDN-008, targeting IgG-mediated autoimmune disorders with potentially superior efficacy.
Analysts’ Opinion of VRDN
Many brokerage firms have already submitted their reports for VRDN stocks, with Wells Fargo repeating the rating for VRDN by listing it as a “Equal Weight.” The predicted price for VRDN in the upcoming period, according to Wells Fargo is $27 based on the research report published on December 19, 2024 of the previous year 2024.
Needham gave a rating of “Buy” to VRDN, setting the target price at $38 in the report published on September 11th of the previous year.
VRDN Trading at -17.85% from the 50-Day Moving Average
After a stumble in the market that brought VRDN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.01% of loss for the given period.
Volatility was left at 6.61%, however, over the last 30 days, the volatility rate increased by 6.62%, as shares sank -6.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.95% lower at present.
During the last 5 trading sessions, VRDN fell by -15.99%, which changed the moving average for the period of 200-days by -3.71% in comparison to the 20-day moving average, which settled at $19.34. In addition, Viridian Therapeutics Inc saw -12.05% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRDN starting from Beetham Thomas W., who purchase 5,000 shares at the price of $23.41 back on Sep 27 ’24. After this action, Beetham Thomas W. now owns 6,000 shares of Viridian Therapeutics Inc, valued at $117,050 using the latest closing price.
Mahoney Stephen F., the President and CEO of Viridian Therapeutics Inc, purchase 21,400 shares at $23.33 during a trade that took place back on Sep 27 ’24, which means that Mahoney Stephen F. is holding 21,400 shares at $499,262 based on the most recent closing price.
Stock Fundamentals for VRDN
Current profitability levels for the company are sitting at:
- -937.23 for the present operating margin
- -20.48 for the gross margin
The net margin for Viridian Therapeutics Inc stands at -851.27. The total capital return value is set at -0.39. Equity return is now at value -51.88, with -46.71 for asset returns.
Based on Viridian Therapeutics Inc (VRDN), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -9.33. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -91.19.
Currently, EBITDA for the company is -234.56 million with net debt to EBITDA at 0.71. When we switch over and look at the enterprise to sales, we see a ratio of 3828.88. The receivables turnover for the company is 21.57for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.55.
Conclusion
To put it simply, Viridian Therapeutics Inc (VRDN) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
